The present inventions relates to a process for the selection of anti c-Met antibodiescapable to inhibit both ligand-dependent and ligand-independent activationof c-Met. More particularly, said process is based on the inhibition of the c-Metdimerization. In another aspect, the present invention concerns such antibodiesand compositions comprising such antibodies for the preparation of a medicamentto treat cancer. Diagnosis process and kits are also part of the invention.
